Skip to content

Biohaven BHVN Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
uniQure logo
uniQureQURE
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%
Enterprise value$2.26B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's accrued expenses and other liabilities?
Biohaven (BHVN) reported accrued expenses and other liabilities of -$64.41M in Q1 2026.
How has Biohaven's accrued expenses and other liabilities changed year-over-year?
Biohaven's accrued expenses and other liabilities decreased by 2415.4% year-over-year, from $2.78M to -$64.41M.